Latest News
Parabilis Medicines, Inc.
- Parabilis CEO Mathai Mammen: How a $770 Million IPO Backs a Peptide Platform to Drug "Undruggable" Proteins
- H.C. Wainwright initiates Parabilis Medicines stock coverage with buy rating By Investing.com
- H.C. Wainwright initiates Parabilis Medicines stock coverage with buy rating By Investing.com
- Parabilis Medicines (PBLS) Could Be 35% Undervalued After Fresh Trial Data
- Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free (PBLS)
- Parabilis Medicines to Present Updated Clinical Data for
- Parabilis Medicines, Inc. (PBLS) - What Are Analysts Saying About This Stock?
- Parabilis begins dose-ranging study of zolucatetide in FAP patients By Investing.com
- Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
- Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 7.6% - What's Next?
- Parabilis Medicines (NASDAQ:PBLS) Shares Down 5.2% - Time to Sell?
- Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up - Time to Buy?
Headlines from the last 30 days, linking to the original publishers. See all market news →